89bio's Q2 Losses Widen Amid Increased R&D for Pegozafermin

TL;DR

**89bio is burning cash fast on R&D, so don't expect profits anytime soon; it's a high-risk bet on pegozafermin's success.**

AI Summary

89bio, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company experienced a net loss of $68.4 million for the three months ended June 30, 2025, an increase from a net loss of $58.1 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $134.5 million, up from $112.3 million in the prior year. Research and development expenses significantly increased to $59.5 million for the three months ended June 30, 2025, from $49.7 million in 2024, primarily due to advancing clinical trials for pegozafermin. General and administrative expenses also rose to $10.1 million from $8.9 million in the comparative three-month periods. The company's cash and cash equivalents stood at $375.2 million as of June 30, 2025, compared to $450.0 million at December 31, 2024, indicating a substantial burn rate. A key strategic move was the entry into a $150.0 million term loan facility in June 2025, with $50.0 million drawn immediately, providing additional liquidity. The company also issued pre-funded warrants and common stock through a follow-on offering in Q1 2025, raising capital to support its clinical programs.

Why It Matters

For investors, 89bio's widening net losses and significant cash burn highlight the inherent risks of clinical-stage biotechnology. The increased R&D spend, while necessary for advancing pegozafermin, means profitability remains a distant prospect, requiring continued capital raises. Employees face job security tied to successful clinical outcomes and sustained funding. Customers, specifically future patients, are directly impacted by the progress of pegozafermin, a potential treatment for metabolic diseases. In the competitive landscape, 89bio's ability to secure funding and achieve positive trial results will dictate its long-term viability against larger pharmaceutical players in the metabolic disease space.

Risk Assessment

Risk Level: high — The company reported a net loss of $134.5 million for the six months ended June 30, 2025, and has no revenue, indicating a complete reliance on financing. Cash and cash equivalents decreased from $450.0 million at December 31, 2024, to $375.2 million at June 30, 2025, demonstrating a substantial cash burn rate of approximately $75 million in six months. This high burn rate, coupled with the inherent uncertainties of clinical trials, presents significant financial risk.

Analyst Insight

Investors should closely monitor the clinical trial progress of pegozafermin and the company's cash runway. Given the high burn rate and lack of revenue, consider this a speculative investment with potential for high reward if pegozafermin succeeds, but also significant risk of capital loss if trials fail or further dilution occurs.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$68.4M

eps

N/A

gross Margin

N/A

cash Position

$375.2M

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue reported for Q2 and H1 2025, consistent with clinical-stage operations.)
• $68.4M — Net Loss (Q2 2025) (Increased from $58.1M in Q2 2024, reflecting higher operating expenses.)
• $134.5M — Net Loss (H1 2025) (Increased from $112.3M in H1 2024, indicating growing operational costs.)
• $59.5M — R&D Expense (Q2 2025) (Increased from $49.7M in Q2 2024, driven by pegozafermin clinical trials.)
• $375.2M — Cash & Equivalents (As of June 30, 2025, down from $450.0M at Dec 31, 2024, showing significant cash burn.)
• $150.0M — Term Loan Facility (New financing secured in June 2025, with $50.0M drawn, providing liquidity.)

Key Players & Entities

• 89bio, Inc. (company) — filer of the 10-Q
• Pegozafermin (product) — primary drug candidate in clinical trials
• $68.4 million (dollar_amount) — net loss for Q2 2025
• $58.1 million (dollar_amount) — net loss for Q2 2024
• $134.5 million (dollar_amount) — net loss for H1 2025
• $112.3 million (dollar_amount) — net loss for H1 2024
• $59.5 million (dollar_amount) — R&D expense for Q2 2025
• $49.7 million (dollar_amount) — R&D expense for Q2 2024
• $375.2 million (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $150.0 million (dollar_amount) — total term loan facility entered in June 2025

FAQ

Risk Factors

• Significant Cash Burn and Need for Future Financing [high — financial]: The company reported a net loss of $68.4 million for Q2 2025 and $134.5 million for H1 2025. Cash and cash equivalents decreased from $450.0 million at the end of 2024 to $375.2 million as of June 30, 2025, indicating a substantial burn rate. While a $150.0 million term loan facility was secured, further financing will likely be required to fund ongoing operations and clinical development.
• Clinical Trial Risks and Delays [high — operational]: The company's primary focus is the advancement of its clinical programs, particularly for pegozafermin. Delays in clinical trials, failure to demonstrate efficacy or safety, or unexpected adverse events can significantly impact development timelines and the potential for regulatory approval and commercialization.
• Regulatory Approval Uncertainty [high — regulatory]: As a clinical-stage company, 89bio is subject to stringent regulatory review processes by agencies like the FDA. The success of its drug candidates hinges on meeting rigorous efficacy and safety standards. Any setbacks or rejections in the regulatory approval process would severely impact the company's prospects.
• Competition in NASH and Other Therapeutic Areas [medium — market]: The biopharmaceutical market, especially for indications like NASH (non-alcoholic steatohepatitis), is highly competitive with numerous companies developing novel therapies. The success of 89bio's pegozafermin will depend on its ability to differentiate and compete effectively against existing and emerging treatments.
• Reliance on Debt Financing [medium — financial]: The recent entry into a $150.0 million term loan facility, with $50.0 million drawn, highlights the company's reliance on debt to fund its operations. This increases financial leverage and introduces interest payment obligations, which could strain resources if revenue generation is delayed.

Industry Context

89bio operates in the highly competitive biopharmaceutical sector, focusing on developing treatments for liver diseases like NASH. The market is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Success hinges on demonstrating clinical efficacy and safety against a backdrop of numerous emerging therapies from both large pharmaceutical companies and smaller biotech firms.

Regulatory Implications

As a clinical-stage company, 89bio faces significant regulatory scrutiny from bodies like the FDA. The path to market approval for pegozafermin requires successful completion of rigorous clinical trials demonstrating safety and efficacy. Any delays or adverse findings in these trials could jeopardize regulatory approval and future commercialization.

What Investors Should Do

1. Monitor clinical trial progress and data readouts for pegozafermin.
2. Assess the company's cash runway and future financing needs.
3. Evaluate the competitive landscape for NASH treatments.

Key Dates

• 2025-06-30: End of Q2 2025 — Reporting period for the 10-Q, showing increased net loss and significant cash burn, offset by new debt financing.
• 2025-06-01: Term Loan Facility Agreement — Secured $150.0 million in debt financing, with $50.0 million drawn, to bolster liquidity for clinical development.
• 2025-01-01: Start of H1 2025 — Beginning of the six-month period marked by continued operational losses and R&D investment.
• 2025-01-01: Follow-on Offering (Q1 2025) — Capital raised through issuance of pre-funded warrants and common stock to support clinical programs.
• 2024-12-31: End of Fiscal Year 2024 — Previous reporting period for comparison, showing higher cash reserves ($450.0M) before the recent burn.

Glossary

Clinical-Stage

A company that is in the process of testing drug candidates in human clinical trials, but has not yet received regulatory approval to market its products. (Explains why 89bio has no revenue and incurs significant R&D expenses.)

Pegozafermin

89bio's lead drug candidate, currently in clinical development for conditions such as NASH. (The primary driver of the company's R&D expenses and future revenue potential.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period, resulting in a negative profit. (Indicates the company's current financial performance, showing increasing losses in Q2 and H1 2025.)

Cash Burn Rate

The rate at which a company is spending its cash reserves, typically used for companies that are not yet profitable. (Highlights the rapid depletion of cash reserves, necessitating careful financial management and future funding.)

Term Loan Facility

A type of loan from a bank or other financial institution that is repaid over a fixed period of time, often used for significant capital expenditures or operational funding. (Represents a new source of liquidity for 89bio, but also adds debt obligations.)

Pre-funded Warrants

A type of warrant that allows the holder to purchase shares of common stock at a nominal exercise price, often used in financing rounds to provide immediate capital while deferring dilution. (Indicates a capital-raising activity undertaken by the company in Q1 2025.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, 89bio has seen an increase in its net loss, with Q2 2025 losses at $68.4 million versus $58.1 million in Q2 2024, and H1 2025 losses at $134.5 million versus $112.3 million in H1 2024. This widening loss is primarily driven by a significant increase in R&D expenses, from $49.7 million in Q2 2024 to $59.5 million in Q2 2025, reflecting the advancement of clinical trials. While cash reserves have decreased from $450.0 million at year-end 2024 to $375.2 million, the company has bolstered liquidity through a new $150.0 million term loan facility, a strategic move not present in the prior year's reporting.

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share ETNB Nasdaq Global Market

Filing Documents

• etnb-20250630.htm (10-Q) — 2211KB
• etnb-ex10_1.htm (EX-10.1) — 16KB
• etnb-ex10_2.htm (EX-10.2) — 40KB
• etnb-ex31_1.htm (EX-31.1) — 16KB
• etnb-ex31_2.htm (EX-31.2) — 16KB
• etnb-ex32.htm (EX-32) — 17KB
• img164203169_0.jpg (GRAPHIC) — 12KB
• 0000950170-25-105939.txt ( ) — 8745KB
• etnb-20250630.xsd (EX-101.SCH) — 1102KB
• etnb-20250630_htm.xml (XML) — 1665KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements of Stockholders' Equity 3 Condensed Consolidated Statements of Cash Flows 5 Notes to Unaudited Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26 PART II. OTHER INFORMATION 27 Item 1.

Legal Proceedings

Legal Proceedings 27 Item 1A.

Risk Factors

Risk Factors 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 49 Item 3. Default Upon Senior Securities 49 Item 4. Mine Safety Disclosures 49 Item 5. Other Information 49 Item 6. Exhibits 50

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Financ ial Statements

Item 1. Financ ial Statements. 89bio, Inc. Condensed Consolida ted Balance Sheets (Unaudited) (In thousands, except share and per share amounts) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 129,076 $ 126,060 Marketable securities 432,088 313,895 Prepaid and other current assets 40,356 36,495 Total current assets 601,520 476,450 Property and equipment, net 77 23 Operating lease right-of-use assets 1,256 1,572 Other assets 632 640 Total assets $ 603,485 $ 478,685 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 14,657 $ 15,382 Accrued expenses 24,170 20,020 Operating lease liabilities, current 784 727 Total current liabilities 39,611 36,129 Operating lease liabilities, noncurrent 679 1,090 Warrant liability — 516 Term loan, noncurrent, net 36,156 35,732 Other noncurrent liabilities 5,306 4,429 Total liabilities 81,752 77,896 Commitments and contingencies (Note 5) Stockholders' equity: Common stock, $ 0.001 par value: 200,000,000 shares authorized; 148,304,875 and 119,849,436 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 148 120 Additional paid-in capital 1,528,753 1,224,617 Accumulated other comprehensive income 122 563 Accumulated deficit ( 1,007,290 ) ( 824,511 ) Total stockholders' equity 521,733 400,789 Total liabilities and stockholders' equity $ 603,485 $ 478,685 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 89bio, Inc. Condensed Consolidated Statements o f Operations and Comprehensive Loss (Unaudited) (In thousands, except share and per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 103,902 $

View Full Filing

View this 10-Q filing on SEC EDGAR